| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,140 |
3,299 |
$659K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,305 |
2,260 |
$551K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,186 |
1,245 |
$389K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
3,485 |
2,257 |
$271K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
4,256 |
2,548 |
$199K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
964 |
218 |
$158K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
2,398 |
659 |
$154K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,948 |
1,457 |
$86K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
857 |
571 |
$58K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,110 |
659 |
$56K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
883 |
676 |
$55K |
| 80306 |
|
4,853 |
2,582 |
$49K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
71 |
63 |
$47K |
| 71046 |
Radiologic examination, chest; 2 views |
721 |
463 |
$43K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
3,687 |
3,316 |
$43K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
527 |
472 |
$41K |
| 70450 |
Computed tomography, head or brain; without contrast material |
258 |
158 |
$40K |
| 80053 |
Comprehensive metabolic panel |
7,493 |
5,523 |
$40K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,635 |
1,405 |
$37K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
310 |
239 |
$37K |
| 87631 |
|
407 |
376 |
$34K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,367 |
1,010 |
$32K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
8,571 |
6,023 |
$31K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
301 |
171 |
$28K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
1,561 |
1,392 |
$25K |
| 80061 |
Lipid panel |
2,239 |
2,034 |
$25K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
492 |
357 |
$23K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
221 |
206 |
$21K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,990 |
1,680 |
$19K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,150 |
473 |
$18K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
132 |
87 |
$14K |
| 73630 |
|
163 |
138 |
$13K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,556 |
1,956 |
$12K |
| 71045 |
Radiologic examination, chest; single view |
423 |
276 |
$12K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,592 |
1,418 |
$12K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
115 |
102 |
$11K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,163 |
1,036 |
$11K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
476 |
425 |
$11K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
110 |
78 |
$8K |
| 90682 |
|
311 |
294 |
$8K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
290 |
242 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
637 |
425 |
$6K |
| 36415 |
Collection of venous blood by venipuncture |
11,416 |
8,533 |
$6K |
| 83735 |
|
1,314 |
989 |
$5K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
103 |
71 |
$5K |
| 84484 |
|
1,440 |
820 |
$5K |
| 80076 |
|
773 |
674 |
$5K |
| 87081 |
|
913 |
819 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
433 |
367 |
$4K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
94 |
25 |
$4K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
879 |
665 |
$3K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
142 |
88 |
$3K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
16 |
12 |
$3K |
| 81001 |
|
1,649 |
1,236 |
$3K |
| 81025 |
|
499 |
418 |
$3K |
| J3490 |
Unclassified drugs |
1,407 |
530 |
$3K |
| 73610 |
|
19 |
12 |
$2K |
| 80305 |
|
231 |
189 |
$2K |
| 83690 |
|
537 |
422 |
$2K |
| 90670 |
|
311 |
281 |
$2K |
| 82607 |
|
156 |
138 |
$1K |
| 86140 |
|
456 |
353 |
$1K |
| 85610 |
|
569 |
353 |
$1K |
| 81002 |
|
872 |
708 |
$1K |
| 97162 |
|
15 |
13 |
$1K |
| 87276 |
|
162 |
122 |
$1K |
| 85027 |
|
262 |
233 |
$1K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
58 |
51 |
$1K |
| 87275 |
|
169 |
125 |
$1K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
16 |
12 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
481 |
354 |
$906.93 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
44 |
37 |
$849.85 |
| 90715 |
|
51 |
51 |
$730.17 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
59 |
38 |
$704.38 |
| 82728 |
|
47 |
40 |
$592.26 |
| 90837 |
Psychotherapy, 53 minutes with patient |
45 |
28 |
$563.05 |
| 85651 |
|
150 |
124 |
$397.39 |
| 87077 |
|
85 |
61 |
$366.37 |
| 83655 |
|
31 |
29 |
$348.00 |
| 83550 |
|
47 |
43 |
$322.09 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
359 |
271 |
$315.66 |
| 87186 |
|
72 |
48 |
$309.27 |
| 90651 |
|
111 |
108 |
$304.57 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
12 |
12 |
$279.51 |
| 82746 |
|
22 |
16 |
$265.68 |
| 82948 |
|
25 |
12 |
$255.22 |
| 83540 |
|
49 |
44 |
$245.00 |
| 90473 |
|
26 |
24 |
$238.39 |
| G0008 |
Administration of influenza virus vaccine |
13 |
13 |
$215.33 |
| 80050 |
General health panel |
25 |
25 |
$199.80 |
| 84439 |
|
34 |
25 |
$192.98 |
| 84703 |
|
32 |
30 |
$175.41 |
| 86803 |
|
14 |
12 |
$173.32 |
| 85018 |
|
74 |
69 |
$153.68 |
| 90686 |
|
863 |
795 |
$145.38 |
| 87070 |
|
12 |
12 |
$73.94 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
35 |
26 |
$71.25 |
| 85652 |
|
34 |
29 |
$64.38 |
| 90723 |
|
130 |
120 |
$0.00 |
| 90680 |
|
69 |
65 |
$0.00 |
| 90633 |
|
188 |
173 |
$0.00 |
| 90648 |
|
266 |
242 |
$0.00 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
48 |
39 |
$0.00 |
| 90734 |
|
45 |
40 |
$0.00 |